Mira Pharmaceuticals (FRA:K6S) ROCE % : -188.23% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Mira Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mira Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2024 was -188.23%.

Mira Pharmaceuticals ROCE % Historical Data

The historical data trend for Mira Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals ROCE % Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-95.20

-876.55

-443.20

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial					-	-	-269.55	-192.45	-188.23

Mira Pharmaceuticals ROCE % Calculation

Mira Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.818	/	( ( (0.81 - 1.293)	+	(4.523 - 0.512) )	/ 2 )
	=	-7.818	/	( (-0.483	+	4.011)	/ 2 )
	=	-7.818	/	1.764
	=	-443.20 %

Mira Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-6.508	/	( ( (4.523 - 0.512)	+	(3.504 - 0.6) )	/ 2 )
	=	-6.508	/	( ( 4.011	+	2.904 )	/ 2 )
	=	-6.508	/	3.4575
	=	-188.23 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Mira Pharmaceuticals (FRA:K6S) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mira Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals (FRA:K6S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (FRA:K6S) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MIRA:USA

Address

855 N Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Its target patient population is also typically presenting with chronic pain. its drug candidate, MIRA1a, if approved by the FDA, maybe a significant advancement in the treatment of neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the company, it believes that MIRA1a enhances the therapeutic potential for treating anxiety, cognitive decline and chronic pain.

Mira Pharmaceuticals (FRA:K6S) Headlines

No Headlines